Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

HC Wainwright & Co. Maintains Buy on eFFECTOR Therapeutics, Adjusts Price Target To $24

Author: Benzinga Newsdesk | February 06, 2024 12:02pm

HC Wainwright & Co. analyst Robert Burns maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy, adjusts target to $24 from $5.

Posted In: EFTR